Javidi-Sharifi N. and coauthors demonstrated that FGF-2 expression was increased in IM-resistant GIST cells, and KIT- and FGFR-3 inhibitors synergized to inhibit GISTs growth in vitro, thereby suggesting the crosstalk between KIT and FGFR3 in GISTs [18]. The gene discussed is FGFR3; the disease is gastrointestinal stromal tumor.